Literature DB >> 1361113

Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin.

K Fuxe1, G Von Euler, L F Agnati, E Merlo Pich, W T O'Connor, S Tanganelli, X M Li, B Tinner, A Cintra, C Carani.   

Abstract

Evidence has been presented that behavioral actions of NT, inducing its neuroleptic-like action, can be explained on the basis of NT-D2 intramembrane receptor-receptor interactions in the basal ganglia, unrelated to the coexistence phenomenon, leading to reduced affinity and transduction of the D2 agonist binding site. By reducing selectively D2 receptor transduction at the pre- and postsynaptic level, the NT receptor appears capable of switching the DA synapses towards a D1 receptor-mediated transduction, illustrating how receptor-receptor interactions can increase the functional plasticity of central synapses (FIG. 12).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361113     DOI: 10.1111/j.1749-6632.1992.tb27350.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  27 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 2.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats.

Authors:  Michal Krawczyk; Xenos Mason; Julian DeBacker; Robyn Sharma; Catherine P Normandeau; Emily R Hawken; Cynthia Di Prospero; Cindy Chiang; Audrey Martinez; Andrea A Jones; Évelyne Doudnikoff; Stephanie Caille; Erwan Bézard; François Georges; Éric C Dumont
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

4.  Co-localization patterns of neurotensin receptor 1 and tyrosine hydroxylase in brain regions involved in motivation and social behavior in male European starlings.

Authors:  Devin P Merullo; Jeremy A Spool; Changjiu Zhao; Lauren V Riters
Journal:  J Chem Neuroanat       Date:  2018-01-31       Impact factor: 3.052

5.  Clozapine administration modifies neurotensin effect on synaptosomal membrane Na+, K+ -ATPase activity.

Authors:  María G López Ordieres; Georgina Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2009-12       Impact factor: 3.996

Review 6.  Receptor-receptor interactions as an integrative mechanism in nerve cells.

Authors:  M Zoli; L F Agnati; P B Hedlund; X M Li; S Ferré; K Fuxe
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

7.  Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Authors:  Yanqi Liang; Mona Boules; Zhimin Li; Katrina Williams; Tomofumi Miura; Alfredo Oliveros; Elliott Richelson
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

8.  The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop.

Authors:  L Ferraro; T Antonelli; W T O'Connor; K Fuxe; P Soubrié; S Tanganelli
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

9.  Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.

Authors:  Catherine Pillot; Jordi Ortiz; Anne Héron; Sophie Ridray; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.